Is FOCL or PAVM more profitable?

FocalTherics has a net margin of -56.26% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% PAVmed -10,794.64% -126.43% -25.49%

Which has better valuation & earnings, OWLT or PAVM?

PAVmed has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $105.70M 1.39 -$39.68M -$0.75 N/A PAVmed $70K 581.71 $400K -$16.05 N/A

Is OWLT or PAVM more profitable?

Owlet has a net margin of -8.61% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets Owlet -8.61% -601.24% -15.96% PAVmed -10,794.64% -126.43% -25.49%

Do analysts prefer INGN or PAVM?

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,000.20%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, INGN or PAVM?

PAVmed has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.41 -$22.75M -$0.90 N/A PAVmed $70K 581.71 $400K -$16.05 N/A

Is INGN or PAVM more profitable?

Inogen has a net margin of -6.94% compared to PAVmed's net margin of -10,794.64%. Inogen's return on equity of -13.17% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% PAVmed -10,794.64% -126.43% -25.49%

Is APYX or PAVM more profitable?

Apyx Medical has a net margin of -14.78% compared to PAVmed's net margin of -10,794.64%. Apyx Medical's return on equity of -76.60% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% PAVmed -10,794.64% -126.43% -25.49%

PAVmed (PAVM) Competitors

$5.09 -0.26 (-4.86%)

As of 09/3/2026 04:00 PM Eastern

Compare

PAVM vs. FOCL, OWLT, KRMD, INGN, and APYX

Should you buy PAVmed stock or one of its competitors? PAVmed's main competitors and comparable companies include FocalTherics (FOCL), Owlet (OWLT), KORU Medical Systems (KRMD), Inogen (INGN), and Apyx Medical (APYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does PAVmed compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

FocalTherics has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

PAVmed has lower revenue, but higher earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.22	-$29.25M	-$1.03	N/A
PAVmed	$70K	581.71	$400K	-$16.05	N/A

In the previous week, FocalTherics had 2 more articles in the media than PAVmed. MarketBeat recorded 2 mentions for FocalTherics and 0 mentions for PAVmed. FocalTherics' average media sentiment score of 0.67 beat PAVmed's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Positive
PAVmed	Neutral

FocalTherics has a net margin of -56.26% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
PAVmed	-10,794.64%	-126.43%	-25.49%

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

FocalTherics presently has a consensus target price of $7.75, suggesting a potential upside of 85.85%. PAVmed has a consensus target price of $56.00, suggesting a potential upside of 1,000.20%. Given PAVmed's higher probable upside, analysts clearly believe PAVmed is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

FocalTherics and PAVmed tied by winning 8 of the 16 factors compared between the two stocks.

How does PAVmed compare to Owlet?

Owlet (NYSE:OWLT) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Owlet has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Owlet has a net margin of -8.61% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
PAVmed	-10,794.64%	-126.43%	-25.49%

72.6% of Owlet shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 36.2% of Owlet shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PAVmed has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70M	1.39	-$39.68M	-$0.75	N/A
PAVmed	$70K	581.71	$400K	-$16.05	N/A

In the previous week, Owlet's average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

Company	Overall Sentiment
Owlet	Neutral
PAVmed	Neutral

Owlet currently has a consensus price target of $15.00, suggesting a potential upside of 198.80%. PAVmed has a consensus price target of $56.00, suggesting a potential upside of 1,000.20%. Given PAVmed's higher possible upside, analysts clearly believe PAVmed is more favorable than Owlet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Owlet beats PAVmed on 9 of the 14 factors compared between the two stocks.

How does PAVmed compare to KORU Medical Systems?

PAVmed (NASDAQ:PAVM) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, KORU Medical Systems had 1 more articles in the media than PAVmed. MarketBeat recorded 1 mentions for KORU Medical Systems and 0 mentions for PAVmed. PAVmed's average media sentiment score of 0.00 equaled KORU Medical Systems'average media sentiment score.

Company	Overall Sentiment
PAVmed	Neutral
KORU Medical Systems	Neutral

PAVmed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

KORU Medical Systems has a net margin of -4.03% compared to PAVmed's net margin of -10,794.64%. KORU Medical Systems' return on equity of -10.63% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
KORU Medical Systems	-4.03%	-10.63%	-6.51%

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 1,000.20%. KORU Medical Systems has a consensus target price of $7.00, indicating a potential upside of 117.39%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

19.9% of PAVmed shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 18.5% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PAVmed has higher earnings, but lower revenue than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	581.71	$400K	-$16.05	N/A
KORU Medical Systems	$41.13M	3.60	-$2.64M	-$0.04	N/A

Summary

KORU Medical Systems beats PAVmed on 10 of the 15 factors compared between the two stocks.

How does PAVmed compare to Inogen?

Inogen (NASDAQ:INGN) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Inogen has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, Inogen had 1 more articles in the media than PAVmed. MarketBeat recorded 1 mentions for Inogen and 0 mentions for PAVmed. Inogen's average media sentiment score of 0.59 beat PAVmed's score of 0.00 indicating that Inogen is being referred to more favorably in the media.

Company	Overall Sentiment
Inogen	Positive
PAVmed	Neutral

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,000.20%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PAVmed has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A
PAVmed	$70K	581.71	$400K	-$16.05	N/A

Inogen has a net margin of -6.94% compared to PAVmed's net margin of -10,794.64%. Inogen's return on equity of -13.17% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
PAVmed	-10,794.64%	-126.43%	-25.49%

89.9% of Inogen shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 13.4% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inogen beats PAVmed on 11 of the 17 factors compared between the two stocks.

How does PAVmed compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 15.9% of Apyx Medical shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PAVmed has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.44	-$11.21M	-$0.20	N/A
PAVmed	$70K	581.71	$400K	-$16.05	N/A

In the previous week, Apyx Medical had 3 more articles in the media than PAVmed. MarketBeat recorded 3 mentions for Apyx Medical and 0 mentions for PAVmed. Apyx Medical's average media sentiment score of 0.85 beat PAVmed's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Apyx Medical	Positive
PAVmed	Neutral

Apyx Medical has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Apyx Medical presently has a consensus target price of $6.60, indicating a potential upside of 115.69%. PAVmed has a consensus target price of $56.00, indicating a potential upside of 1,000.20%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apyx Medical has a net margin of -14.78% compared to PAVmed's net margin of -10,794.64%. Apyx Medical's return on equity of -76.60% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
PAVmed	-10,794.64%	-126.43%	-25.49%

Summary

Apyx Medical beats PAVmed on 13 of the 17 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.78M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.32	25.92	273.29	25.38
Price / Sales	581.71	73.28	613.45	92.55
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	2.64	6.04	12.89	6.14
Net Income	$400K	$150.03M	$3.47B	$349.01M
7 Day Performance	3.46%	-1.32%	0.60%	-0.27%
1 Month Performance	0.99%	1.27%	5.73%	0.68%
1 Year Performance	-61.80%	9.88%	25.35%	14.84%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PAVM PAVmed	1.8747 of 5 stars	$5.09 -4.9%	$56.00 +1,000.2%	-63.9%	$42.78M	$70K	N/A	90
FOCL FocalTherics	4.3387 of 5 stars	$4.39 +5.0%	$7.75 +76.5%	N/A	$156.87M	$70.53M	N/A	230
OWLT Owlet	2.3523 of 5 stars	$5.20 +2.3%	$15.00 +188.6%	-32.2%	$148.45M	$105.70M	N/A	106
KRMD KORU Medical Systems	3.3982 of 5 stars	$3.21 -0.3%	$7.00 +118.1%	-20.3%	$147.90M	$41.13M	N/A	80
INGN Inogen	0.7689 of 5 stars	$5.54 +0.7%	N/A	-30.8%	$145.96M	$348.67M	N/A	1,030

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors